All

All
Insight
Research Services
Preclinical CRO
Animal Resource Bank

中文 English

Prostate cancer CDX animal model

Explore more

On this page

Model Introduction

Platform Service Advantages

Model Construction

Publish an article

2026-10-29

Naming Genetically Engineered Mice (Part II): From Being Understandable to Being Written Correctly

2026-10-29

How should a multi-disease composite mouse model be constructed? Let’s take a look at the CKM approach.

2026-08-12

2026 CKM Guidelines Released: Chronic Diseases Enter the Era of Integrated Cardiorenal-Metabolic Management—It’s Time to Rethink Animal Models

2026-08-12

A Guide to Safe Mouse Handling | Manual on Mouse Transport Protocols and Troubleshooting

2026-08-08

Standardized Modeling Platform for Endometriosis: Recreating Inflammatory Pathology to Accelerate the Validation of New Gynecological Therapeutics

2026-07-31

In vivo CRISPR library screening: How to pinpoint true signals amid vast numbers of cells and complex tissues?

Prostate cancer

Introduction to the CDX Animal Model

The prostate cancer CDX (cell line–derived xenograft) animal model is a classic tumor model in which human prostate cancer cell lines are implanted subcutaneously or orthotopically into immunodeficient mice, enabling robust recapitulation of key biological features such as tumor growth, angiogenesis, and local invasion. This model offers advantages including high tumorigenicity, excellent reproducibility, and well-established experimental protocols, making it a reliable preclinical platform for investigating the mechanisms of prostate cancer initiation and progression, evaluating drug sensitivity, and developing novel therapeutic strategies.

Advantages of Aniphe BioLab’s CDX Animal Model Platform Services

Ailinfei maintains an ample stock of prostate cancer CDX model cell lines, with well-established and stable tumor‑engraftment models, and offers comprehensive in vivo efficacy evaluation services, providing robust support for preclinical drug development in prostate cancer.

	Cell resources are abundant. A diverse array of classic human prostate cancer cell lines is available, with the option to expand and passage them as needed, enabling rapid initiation of implantation and tumor‑bearing model generation.
	Tumor-forming efficacy is stable. Standardized subcutaneous injection procedures yield a high tumor‑formation rate, uniform tumor growth, and minimal intergroup variability in data.
	One-stop pharmacological services We provide end-to-end services, including model establishment, animal housing, regular tumor volume measurements, blood sampling, and terminal necropsy with histopathological analysis.
	Flexible Customization Solutions The vaccination dose, grouping, and dosing schedule can be adjusted, while combination therapies and resistance‑related studies are conducted concurrently.
	Strict quality control throughout the entire process. Regularly record tumor measurements and animal body weights, maintain complete raw data, and ensure that the reporting format complies with regulatory submission requirements.
	Fast delivery Hot‑selling cell lines are available for immediate expansion, with streamlined scheduling to shorten the overall experimental R&D timeline.

Modeling cycle	About 10 days
Laboratory animals	Mice and rats of SPF grade
Positive drug	Commonly used agents such as docetaxel, enzalutamide, abiraterone, and bicalutamide serve as positive controls and exert antitumor effects by inhibiting tumor proliferation and blocking the androgen receptor signaling pathway.
Application areas	It is primarily used for research on the pathogenesis of prostate cancer, screening of anti-tumor and endocrine‑targeted therapies, evaluation of drug efficacy, and preclinical studies aimed at precision medicine and the development of innovative treatment strategies.

Experimental results

Construction of the CDX animal model

01 RM1 Orthotopic CDX: RM1 prostate cancer cells derived from the same strain are orthotopically injected into the mouse prostate tissue. With a fully intact immune system, this model can mimic tumor‑intrinsic invasion and metastasis, making it suitable for studies of immune‑mediated antitumor responses.

02 TRAMP transgenic model: A prostate-specific expression of an oncogene leads to the spontaneous, progressive development of prostate tumors and distant metastasis in male mice, eliminating the need for surgical tumor induction and making it well suited for long-term studies on tumor progression and drug resistance mechanisms.

In vivo imaging detection

In vivo fluorescence imaging of mice. Fluorescently labeled prostate cancer cells were orthotopically implanted into the mouse prostate, and fluorescence signals were acquired using an in vivo optical imaging system. In the figure, a prominent high‑intensity fluorescence signal is evident in the pelvic prostate region, with fluorescence concentrated in this area, indicating stable tumor formation at the primary site, clear visualization of the tumor burden, and no obvious distant metastatic fluorescence signals.